Health Economics›Non-small cell lung cancer›Advanced or metastatic disease ROS1 inhibitor-exposed

Advanced or metastatic disease ROS1 inhibitor-exposed

Non-small cell lung cancer · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Repotrectinib monotherapy Variant #01 Partial	ROS1	—	28d	—	—	~2	—	—
Lorlatinib monotherapy Variant #01 Partial	ROS1	—	28d	—	—	2	—	2

2 of 2 regimens shown